Daniel Portalez
Overview
Explore the profile of Daniel Portalez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
224
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Couchoux T, Jaouen T, Melodelima-Gonindard C, Baseilhac P, Branchu A, Arfi N, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):1113-1122.
PMID: 38493072
Background And Objective: Prostate multiparametric magnetic resonance imaging (MRI) shows high sensitivity for International Society of Urological Pathology grade group (GG) ≥2 cancers. Many artificial intelligence algorithms have shown promising...
2.
Bajeot A, Covin B, Meyrignac O, Pericart S, Aziza R, Portalez D, et al.
Eur Urol Oncol
. 2021 Jun;
5(3):296-303.
PMID: 34154979
Background: Discordant findings between multiparametric magnetic resonance imaging (mpMRI) and transrectal image-guided biopsies of the prostate (TRUS-P) may result in inadequate risk stratification of localized prostate cancer. Objective: To assess...
3.
Ploussard G, Beauval J, Renard-Penna R, Lesourd M, Manceau C, Almeras C, et al.
J Clin Med
. 2020 Jan;
9(1).
PMID: 31952120
Background: To study the impact of MRI characteristics and of targeted biopsy (TB) core number on the final grade group (GG) prediction. Materials And Methods: The cohort was 478 consecutive...
4.
Ploussard G, Beauval J, Lesourd M, Almeras C, Assoun J, Aziza R, et al.
Urology
. 2020 Jan;
137:126-132.
PMID: 31899229
Objective: To assess the impact of concomitant targeted biopsies (TB) for predicting final disease reclassification in MRI-positive low-risk prostate cancer patients eligible for active surveillance (AS) on systematic biopsies (SB)....
5.
Ploussard G, Beauval J, Lesourd M, Manceau C, Almeras C, Aziza R, et al.
World J Urol
. 2019 Oct;
38(7):1735-1740.
PMID: 31612251
Purpose: To assess the final pathology risk in MRI-positive grade group (GG) 2 prostate cancer (PCa) patients undergoing targeted (TB) and systematic (SB) biopsies, and thereby, the possibility of active...
6.
Ploussard G, Beauval J, Lesourd M, Almeras C, Assoun J, Aziza R, et al.
J Urol
. 2019 Jun;
202(6):1182-1187.
PMID: 31246548
Purpose: We assessed the added value of concomitant systematic biopsy for final grade group prediction in patients with positive magnetic resonance imaging who were undergoing targeted biopsy. Materials And Methods:...
7.
Ploussard G, Beauval J, Lesourd M, Almeras C, Assoun J, Aziza R, et al.
World J Urol
. 2019 Jun;
38(3):663-671.
PMID: 31197523
Purpose: To assess the upstaging/upgrading rates of low-risk prostate cancer (PCa) according to the biopsy scheme used (systematic (SB), targeted biopsies (TB), or both) in the setting of positive pre-biopsy...
8.
Covin B, Roumiguie M, Quintyn-Ranty M, Graff P, Khalifa J, Aziza R, et al.
World J Urol
. 2018 Aug;
37(2):269-275.
PMID: 30145777
Purpose: To evaluate image-guided Transperineal Elastic-Registration biopsy (TPER-B) in the risk-stratification of low-intermediate risk prostate cancer detected by Transrectal-ultrasound biopsy (TRUS-B) when estimates of cancer grade and volume discorded with...
9.
Brun T, Bachaud J, Graff-Cailleaud P, Malavaud B, Portalez D, Popotte C, et al.
Brachytherapy
. 2018 Mar;
17(3):544-555.
PMID: 29525514
Purpose: To present the feasibility study of optimal dose coverage in ultra-focal brachytherapy (UFB) with multiparametric MRI for low- and intermediate-risk prostate cancer. Methods And Materials: UFB provisional dose plans...
10.
Graff P, Portalez D, Lusque A, Brun T, Aziza R, Khalifa J, et al.
Int J Radiat Oncol Biol Phys
. 2018 Mar;
102(4):903-911.
PMID: 29510957
Purpose: Focal therapy of prostate cancer requires precise positioning of therapeutic agents within well-characterized index tumors (ITs). We assessed the feasibility of low-dose-rate ultrafocal brachytherapy. Methods And Materials: The present...